A Simplified Physiology–Laboratory Score (PLS4) for Early Risk Stratification in Acute Cholangitis
- 1Department of Emergency Medicine, College of Medicine, Inha University Hospital, Inha University, 27, Inhang-ro, Jemulpo-gu, Incheon 22332, Republic of Korea
- 2Department of Surgery, College of Medicine, Inha University Hospital, Inha University, Incheon 22332, Republic of Korea
- 3Department of Internal Medicine, College of Medicine, Inha University Hospital, Inha University, Incheon 22332, Republic of Korea
Abstract
Objectives: Acute cholangitis is a common biliary infection in the emergency department (ED) that can progress rapidly to septic shock and multiorgan dysfunction. The Tokyo Guidelines 2018 (TG2018) is the current reference standard for severity assessment but may be cumbersome during the initial ED encounter. We aimed to develop a simplified physiology–laboratory score (PLS4) computable from four routine bedside variables and to compare its early risk-stratification performance with TG2018. Materials and Methods: This single-center retrospective observational cohort study included 482 adult patients with acute cholangitis (International Classification of Diseases, 10th Revision code K83.0) presenting to a tertiary university hospital ED between January 2016 and December 2021. Primary outcomes were ICU admission, vasopressor use, and prolonged hospital stay (length of stay ≥ 14 days); intubation was analyzed as an exploratory outcome. PLS4 assigned 1 point each for albumin < 3.5 g/dL, systolic blood pressure ≤ 100 mmHg, heart rate ≥ 100/min, and prothrombin time–international normalized ratio ≥ 1.2 (range 0–4). Discrimination was assessed by receiver operating characteristic curves, with bootstrap 95% confidence intervals and bootstrap optimism-corrected internal validation. Results: ICU admission occurred in 81 patients (16.8%), vasopressor use in 53 (11.0%), and prolonged stay in 111 (23.0%). The areas under the curve (AUCs) for ICU admission were 0.850 for TG2018 and 0.800 for PLS4 (p = 0.116), and the optimism-corrected AUC of PLS4 was 0.779. For vasopressor use, which is part of the TG2018 grade III definition, the AUCs were 0.936 and 0.843. When PLS4 was added to TG2018, the AUC for ICU admission increased to 0.886. At PLS4 ≥ 3, specificity reached 0.978 for ICU admission and 0.970 for vasopressor use, with event rates rising stepwise from 5.96% to 100% and 2.55% to 90.0%, respectively. Conclusions: In this single-center derivation study, PLS4 showed high specificity and added prognostic information to TG2018. It should be validated in other centers before clinical use.
Related
- Artificial Intelligence in Acute Coronary Syndromes: From Early Diagnosis to Culprit Lesion Characterization, Coronary Physiology, and Risk Stratification
- A three-month physiology score correlates with CLAD after lung transplant.
- Development of a Simplified Clinical Score for Defecation Disorder
- SCORES (Selection of Clinical Observations for Risk Evaluation Scores): Impact of Heart Rate Selection on Simplified Geneva Score Performance in Suspected Pulmonary Embolism
- Prognostic stratification by the ESTRO/EORTC oligometastatic classification and simplified binary approaches in lung cancer patients treated with stereotactic ablative radiotherapy.
BibTeX
@article{lee2026simplified,
title = {{A Simplified Physiology–Laboratory Score (PLS4) for Early Risk Stratification in Acute Cholangitis}},
author = {Jaewon Lee and Moon Suk Choi and Yujin Lee and Jeseop Lee and Jungnam Lee and Tae-Youn Kim},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15207842},
url = {https://www.mdpi.com/2077-0383/15/20/7842},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A Simplified Physiology–Laboratory Score (PLS4) for Early Risk Stratification in Acute Cholangitis
AU - Jaewon Lee
AU - Moon Suk Choi
AU - Yujin Lee
AU - Jeseop Lee
AU - Jungnam Lee
AU - Tae-Youn Kim
PY - 2026
DA - 2026/10/11
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15207842
UR - https://www.mdpi.com/2077-0383/15/20/7842
AB - Objectives: Acute cholangitis is a common biliary infection in the emergency department (ED) that can progress rapidly to septic shock and multiorgan dysfunction. The Tokyo Guidelines 2018 (TG2018) is the current reference standard for severity assessment but may be cumbersome during the initial ED encounter. We aimed to develop a simplified physiology–laboratory score (PLS4) computable from four routine bedside variables and to compare its early risk-stratification performance with TG2018. Materials and Methods: This single-center retrospective observational cohort study included 482 adult patients with acute cholangitis (International Classification of Diseases, 10th Revision code K83.0) presenting to a tertiary university hospital ED between January 2016 and December 2021. Primary outcomes were ICU admission, vasopressor use, and prolonged hospital stay (length of stay ≥ 14 days); intubation was analyzed as an exploratory outcome. PLS4 assigned 1 point each for albumin < 3.5 g/dL, systolic blood pressure ≤ 100 mmHg, heart rate ≥ 100/min, and prothrombin time–international normalized ratio ≥ 1.2 (range 0–4). Discrimination was assessed by receiver operating characteristic curves, with bootstrap 95% confidence intervals and bootstrap optimism-corrected internal validation. Results: ICU admission occurred in 81 patients (16.8%), vasopressor use in 53 (11.0%), and prolonged stay in 111 (23.0%). The areas under the curve (AUCs) for ICU admission were 0.850 for TG2018 and 0.800 for PLS4 (p = 0.116), and the optimism-corrected AUC of PLS4 was 0.779. For vasopressor use, which is part of the TG2018 grade III definition, the AUCs were 0.936 and 0.843. When PLS4 was added to TG2018, the AUC for ICU admission increased to 0.886. At PLS4 ≥ 3, specificity reached 0.978 for ICU admission and 0.970 for vasopressor use, with event rates rising stepwise from 5.96% to 100% and 2.55% to 90.0%, respectively. Conclusions: In this single-center derivation study, PLS4 showed high specificity and added prognostic information to TG2018. It should be validated in other centers before clinical use.
SN - 2077-0383
ER -